Ask AI
ProCE Banner Activity

Patient Perspectives: Individualized Hepatitis B Care

Clinical Thought

The choice people living with HBV have today really boils down to: Do I take medicine or not? With only 3 first-line oral antivirals, treatment individualization for HBV can seem impossible, but healthcare professionals should still take care to include people living with HBV in treatment decisions—think of people first and living with hepatitis B second. Read on for my perspective as the President of the Hepatitis B Foundation. 

Released: October 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Aligos Therapeutics.

Aligos Therapeutics

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients living with chronic hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Outline key limitations of current antiviral therapy for HBV

  • Create individualized HBV therapy goals based on patient factors

  • Evaluate the current evidence on emerging HBV therapies and their potential role in advancing patient care

Financial Disclosures

Primary Author

Chari Cohen, DrPH, MPH: other financial or material support (paid to institution): Aligos, Diasorin, Dynavax, Exact Sciences, Gilead, GSK, GrifolsMirum, nChroma, Paraxel, Precision, Vir; advisor (paid to institution): Gilead, GSK.